Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment.

@article{Xia2019PlasmaCI,
  title={Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment.},
  author={M. Xia and Guichan Liao and Hong-jie Chen and Y. Wu and R. Fan and X. Zhang and J. Peng},
  journal={Clinical immunology},
  year={2019},
  volume={198},
  pages={
          31-38
        }
}
  • M. Xia, Guichan Liao, +4 authors J. Peng
  • Published 2019
  • Medicine
  • Clinical immunology
  • In this study, we investigated whether plasma cytokine/chemokine levels could predict HBsAg loss or clinical relapse (CR) after stopping nucleos(t)ides analogue (NA) treatment. Theplasma cytokines/chemokines levels were measured at 0, 4, 8, 12, 24 and 48 weeks after NA discontinuation by using the enzyme-linked immunoassay (ELISA) kit. Cox regression analysis revealed that CXCL13 level at the end of treatment (EOT) was an independent predictor for CR (HR 0.26, p < 0.001) and HBsAg loss (HR 3.01… CONTINUE READING
    1 Citations

    References

    SHOWING 1-10 OF 38 REFERENCES
    Predictors of Sustained Virologic Response after Discontinuation of Nucleos(t)ide Analog Treatment for Chronic Hepatitis B
    • J. Peng, J. Cao, +4 authors J. Sun
    • Medicine
    • Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    • 2015
    • 12